Janhavi Mishra*, Anas Shaik, Jaya Agnihotri and Mahima Salian

H K College of Pharmacy HK CAMPUS, Adj. Municipal School, Next to MHADA Complex Relief Road, Oshiwara, Jogeshwari (West), Mumbai, Maharashtra, India

*Corresponding Author: Janhavi Mishra, H K College of Pharmacy HK CAMPUS, Adj. Municipal School, Next to MHADA Complex Relief Road, Oshiwara, Jogeshwari (West), Mumbai, Maharashtra, India.

Received: October 17, 2022; Published: November 28, 2022

Abstract

The market for natural products has experienced rapid expansion in recent years. It leads to the creation of numerous proprietary herbal products, the majority of which are composed of multiple ingredients. The development of herbal drug therapies has led to the discovery that many of the drug's components may interact with one another, which has led to severe concerns regarding the stability of such formulations, a crucial topic in the study of phytochemistry and natural medicines. National pharmacovigilance centers (or analogous institutions) will need to have specialized technical knowledge in order to manage herbal medications, in particular, to analyze the reasons of adverse occurrences. This will include qualified professionals in pertinent technical fields and resources to analyze the products in question, for which there is frequently little data and limited access to trustworthy information sources. Additionally, an effort has been made to gather a profile of herbal substances that improve drug bioavailability together with their mechanism of action (where known) and research on this enhancement.

Keywords: Natural Product; Herbal Drug; Phytochemistry; and National Pharmacovigilance Centers

References

1. Addae-Mensah, I., Beltramini, H., Haggag, A. A., Hoogmartens, J., Shaohong, J., Molzon, J. A., Paál, T. L., Van Zyl, A. J., Luigetti, R., Korakianiti, E., Miller, J. H. M. B., Moretto, L. D.
2. Sam AP., et al. “WHO Expert Committee on specifications for pharmaceutical preparations”. In World Health Organization - Technical Report Series (Issue 937).
3. Ahmad,I., et al. “Modern Phytomedicine: turning medicinal plants into drugs”. (Chapter 3) [herbal medicine: prospect and constraints] (2006).
4. Aremu O. “Physico-Chemical Stability Studies of Neem (Azadirachta indica) Seed Oil Cream”. African Research Review3 (2009): 1-11.
5. Bansal G., et al. “Stability Testing of Herbal Drugs: Challenges, Regulatory Compliance and Perspectives”. Phytotherapy Research, December (2015): 1046-1058.
6. Bernatoniene J., et al. “Topical application of calendula officinalis (L.): Formulation and evaluation of hydrophilic cream with antioxidant activity”. Journal of Medicinal Plants Research6 (2011): 868-877.
7. Bhatt P. “Herbal Phytoconstituents Overview: a New Therapeutic Approach in Management of Cardiac Disorders”. International Journal of Pharmaceutical Sciences and Research10 (2013): 3761.
8. Bruni R., et al. “Herbal drug quality and phytochemical composition of Hypericum perforatum L. affected by ash yellows phytoplasma infection”. Journal of Agricultural and Food Chemistry4 (2005): 964-968.
9. Carstens MG., et al. “Poly (ethylene glycol)-oligolactates with monodisperse hydrophobic blocks: Preparation, characterization, and behavior in water”. Langmuir24 (2005): 11446-11454.
10. Code QR. “Kumar et al”. Pharmaceutical Dosage Forms10 (2020): 236-240.
11. Dahiya J., et al. “Chewable Tablets: A Comprehensive Review”. The Pharma Innovation Journal5 (2015): 100-105.
12. Franco P and De Marco I. “The use of poly (N-vinyl pyrrolidone) in the delivery of drugs: A review”. Polymers 5 (2020): 18-21.
13. Green C E., et al. “Extraction, processing, and storage effects on curcuminoids and oleoresin yields from Curcuma longa grown in Jamaica”. Journal of Agricultural and Food Chemistry 56.10 (2008): 3664-3670.
14. Hamidi M., et al. “A Pharmacokinetic Overview of Nanotechnology-Based Drug Delivery Systems: An ADME-Oriented Approach”. Critical Reviews in Therapeutic Drug Carrier Systems5 (2013): 435-467.
15. Hani U E., et al. “Formulation and evaluation of liquisolid compacts of flunarizine hydrochloride”. International Journal of Pharmacy and Technology3 (2015): 7115-7130.
16. Health N and Directorate P. “Health Canada: Evidence for Quality of Finished Natural Health Products” (Issue June) (2007).
17. Houghton P. “Regulation of herbal medicinal products”. Pharmaceutical Journal7549 (2009): 485-486.
18. Hussain K., et al. “A review of the literature and latest advances in research of Piper sarmentosum”. Pharmaceutical Biology8 (2012): 1045-1052.
19. “Ich Q1a (R2). Stability Testing of New Drug Substances and Products” 4 (2003): 24.
20. Iwu M., et al. “Stability of cough linctus (Streptol) formulated from named medicinal plant extracts”. Chemical and Pharmaceutical Bulletin3 (2009): 229-232.
21. Kamurthy H., et al. “Antifungal activity of weed extracts on Candida albicans: An in-vitro study”. International Journal of Phytomedicine3 (2016): 453-456.
22. Khan B., et al. “Formulation and evaluation of antisebum secretion effects of sea buckthorn w/o emulsion”. Journal of Pharmacy and Bioallied Sciences1 (2010): 13.
23. Kim JH., et al. “Global Comparison of Stability Testing Parameters and Testing Methods for Finished Herbal Products”. Evidence-Based Complementary and Alternative Medicine (2019).
24. Kruse SO and Sultan K. “Stability testing of herbal medicinal products”. Innovations in Pharmaceutical Technology 33 (2010): 64-68.
25. Kumadoh D and Ofori-kwakye K. “Considerations-an Overview”. 4.4 (2017).
26. “Standardization of herbal medicines - A review”. International Journal of Biodiversity and Conservation 4.3 (2012): 101-112.
27. Lawson L D and Gardner C D. “Composition, stability, and bioavailability of garlic products used in a clinical trial”. Journal of Agricultural and Food Chemistry16 (2005): 6254-6261.
28. Lefevbre H. Chapter 14 Chapter 14. LR Lloyd’s Register, 100 (2000): 1-35.
29. Mahran RI., et al. “Bringing Curcumin to the Clinic in Cancer Prevention: a Review of Strategies to Enhance Bioavailability and Efficacy”. AAPS Journal1 (2017): 54-81.
30. Naithani V. “United States Patent resistian”. 2.12 (2020).
31. Organisation W H. “Annex 1: WHO guidelines on good herbal processing practices for herbal medicines”. WHO Technical Report Series, No. 1010 (2018): 81-152.
32. Pradhan N., et al. “Who (World Health Organization) Guidelines for Standardization of Herbal Drugs”. International Ayurvedic Medical Journal8 (2015): 2238- 2243.
33. Sawant SS., et al. “Studies on physico-chemical properties of papaya blended aloe vera based health drink”. 7.4 (2018): 1116-1118.
34. Sven B and Kruse O. “Up until recently, Herbal Medicinal Products (HMPs) were mostly marketed in the UK as functional food products under section 12.2 of the Medicines Act”. In line with the harmonisation of legislation on herbal medicines across the EU, Directive 2004/24 EC o. 64-68. www.iptonline.com (2005).
35. Thakur L., et al. “Novel approaches for stability improvement in natural medicines”. Pharmacognosy Reviews9 (2011): 48-54.
36. Ullah N., et al. “A review on general introduction to medicinal plants, its phytochemicals and role of heavy metal and inorganic constituents”. Life Science Journal 11 (2014): 520-527.
37. Variable I., et al. (12) United States Patent ( 10 ) Patent No.: 2 (12). Villiers, M. M. De. 2017. 10,220. July (2011).
38. Wharf C. “European Medicines Agency”. Definitions, July, (2020): 1-6.
39. “Guidelines for Stability Testing of Pharmaceutical Products Containing Well Established Drug Substances in Conventional Dosage Forms”. World Health Organization Technical Report Series 863 (1996): 65-80.
40. Woo C S J., et al. “Herbal Medicine. Toxicity and Recent Trends in Assessing Their Potential Toxic Effects”. In Advances in Botanical Research (1^st, Vol. 62) (2012).
41. Alaerts G., et al. “Recent Developments in Chromatographic Fingerprints from Herbal Products: Set-Up and Data Analysis”. Combinatorial Chemistry and High Throughput Screening10 (2010): 900-922.
42. Dejaegher B., et al. “Methodology to develop liquid chromatographic fingerprints for the quality control of herbal medicines”. Acta Chromatographica 22 (2010): 237-258.
43. Aziz, Namra., et al. “Evaluation of a Polyherbal Powder for Treatment of Diabetes Mellitus” 81 (2019).
44. De Bohner LS., et al. “Quantitative analysis of phospholipids by thin-layer chromatography”. Journal of Chromatography A 17 (1965): 513-519.
45. Reich E and Schibli A. “A standardized approach to modern high-performance thin-layer chromatography (HPTLC)”. JPC – Journal of Planar Chromatography 6 (2004): 438-443.
46. Shepherd RW., et al. “A rapid, sensitive method for accurate analysis of individual bile acids in biological fluids by high-performance thin-layer chromatography and densitometry”. Clinical Biochemistry3 (1978): 106-111.
47. Rao RN and Nagaraju V. “An overview of the recent trends in development of HPLC methods for determination of impurities in drugs”. Journal of Pharmaceutical and Biomedical Analysis 3 (2003): 335-377.
48. Vassort A., et al. “A generic approach to the impurity profiling of drugs using standardized and independent capillary zone electrophoresis methods coupled to electrospray ionization mass spectrometry”. Electrophoresis 9 (2005): 1712-1723.
49. Behera B and Bhattacharya S. “The importance of assessing heavy metals in medicinal herbs: a quantitative study”. TANG [HUMANITAS MEDICINE] 1 (2016): 3.1-3.4.

Citation

Citation: Janhavi Mishra., et al. “Strategies to Enhance the Stability of Herbal Active". Acta Scientific Pharmaceutical Sciences 6.12 (2022): 39-50.

Copyright

Copyright: © 2022 Janhavi Mishra., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.